Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | DAO | P14920 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | FHIT | P49789 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14748325 | 0.85 | HDAC3 (0.49) | ALDH1A1KDM4EMAPTMEN1DAO | |
| SCHEMBL16863717 | 0.83 | GAA (0.50) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL11492438 | 0.82 | KDM4E (0.50) | ALDH1A1KDM4EMAPTMEN1DAO | |
| SCHEMBL6739730 | 0.81 | PTPN2 (0.46) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL8630011 | 0.81 | HDAC3 (0.45) | ALDH1A1KDM4EMAPTHDAC3HDAC4 | |
| SCHEMBL14382851 | 0.81 | HDAC3 (0.45) | ALDH1A1KDM4EMAPTHDAC3HDAC4 | |
| SCHEMBL10109854 | 0.81 | PTPN2 (0.49) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL8629934 | 0.81 | DAO (0.59) | ALDH1A1KDM4EMAPTMEN1DAO | |
| SCHEMBL9925990 | 0.80 | KDM4E (0.67) | ALDH1A1KDM4EMAPTMEN1DAO | |
| SCHEMBL4167116 | 0.79 | ALDH1A1 (0.47) | ALDH1A1KDM4EMAPTHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | UNIVERSITE DE MONTREAL (CA) | 2025-11-25 | — | — | US | disclosed |
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | UNIVERSITE DE MONTREAL (CA) | 2025-08-28 | — | — | US | disclosed |
| US-12139488-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | Université de Montréal (CA) | 2024-11-12 | — | — | US | disclosed |
| US-20240317747-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-09-26 | — | — | US | disclosed |
| US-12060353-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | Université de Montréal (CA) | 2024-08-13 | — | — | US | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| US-20240140945-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-05-02 | — | — | US | disclosed |
| EP-4326719-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-02-28 | — | — | EP | disclosed |
| CN-117177973-A | Pyrido [3,2-D ] pyrimidine compounds and their use for the treatment of proliferative disorders | 蒙特利尔大学 | 2023-12-05 | — | — | CN | disclosed |
| WO-2022221939-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | UNIVERSITE DE MONTREAL (CA) | 2022-10-27 | — | — | WO | disclosed |
| US-20110178074-A1 | ANTIPATHOGENIC BENZAMIDE COMPOUNDS | GENESOFT PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | ALDH1A1 1636/4885KDM4E 2883/4885MAPT 2948/4885 |
| US-20240140945-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | ALDH1A1 1636/4885KDM4E 2883/4885MAPT 2948/4885 |
| US-20240317747-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | ALDH1A1 1636/4885KDM4E 2883/4885MAPT 2948/4885 |
| US-12139488-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, KRAS | ALDH1A1 1636/4885KDM4E 2883/4885MAPT 2948/4885 |
| US-12060353-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, KRAS | ALDH1A1 1636/4885KDM4E 2883/4885MAPT 2948/4885 |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, DPYD | ALDH1A1 1619/4885KDM4E 2840/4885MAPT 3015/4885 |
| US-20110178074-A1 | ANTIPATHOGENIC BENZAMIDE COMPOUNDS | CASP3, BCL3, ME3 | ALDH1A1 1365/4885KDM4E 2794/4885MAPT 4787/4885 |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, DPYD | ALDH1A1 1619/4885KDM4E 2840/4885MAPT 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.